Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Raymond James analyst Chris Raymond initiates coverage on Tyra Biosciences (NASDAQ:TYRA) with a Strong Buy rating and announ...
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Tyra Biosciences (NASDAQ:TYRA) with a Buy and maintains $30 pr...
-Dabogratinib is the only oral FGFR3-selective inhibitor in clinical development for achondroplasia--Initial results from safet...
Tyra Biosciences (NASDAQ:TYRA) reported quarterly losses of $(0.47) per share which beat the analyst consensus estimate of $(0....
Tyra Biosciences, Inc. (NASDAQ:TYRA), a clinical-stage biotechnology company focused on developing next-generation precision me...
HC Wainwright & Co. analyst Mitchell Kapoor reiterates Tyra Biosciences (NASDAQ:TYRA) with a Buy and maintains $30 price...
Piper Sandler analyst Allison Bratzel assumes Tyra Biosciences (NASDAQ:TYRA) with a Overweight rating and announces Price Ta...
Tyra Biosciences (NASDAQ:TYRA) reported quarterly losses of $(0.47) per share which beat the analyst consensus estimate of $(0....
